Statements (54)
Predicate | Object |
---|---|
gptkbp:instanceOf |
gptkb:protein
gptkb:G_protein-coupled_receptor |
gptkbp:activatedBy |
gptkb:Gs_protein
|
gptkbp:binds |
gptkb:adenosine
|
gptkbp:drugClass |
purinergic receptor
|
gptkbp:encodedBy |
ADORA2A gene
|
gptkbp:enemyOf |
gptkb:regadenoson
caffeine CGS-21680 istradefylline |
gptkbp:expressedIn |
brain
heart immune cells |
gptkbp:formsComplexWith |
dopamine D2 receptor
|
gptkbp:foundIn |
gptkb:striatum
|
https://www.w3.org/2000/01/rdf-schema#label |
Adenosine A2a receptor
|
gptkbp:improves |
cAMP production
|
gptkbp:involvedIn |
immunosuppression
neurotransmission sleep regulation cardioprotection vasodilation inflammation modulation |
gptkbp:locatedIn |
gptkb:cell_membrane
|
gptkbp:locatedOnChromosome |
22q11.23
|
gptkbp:modulatedBy |
immune response
motor control platelet aggregation glutamate release T cell activity GABAergic transmission cholinergic transmission histaminergic transmission microglial activation noradrenergic transmission serotonergic transmission |
gptkbp:molecularWeight |
45 kDa
|
gptkbp:OMIM |
102776
|
gptkbp:PDB |
3EML
|
gptkbp:regulates |
dopamine signaling
|
gptkbp:relatedTo |
Adenosine A1 receptor
Adenosine A2b receptor Adenosine A3 receptor |
gptkbp:target |
immunotherapy
anti-inflammatory drugs antiparkinsonian drugs ischemia therapies |
gptkbp:transmembraneDomains |
true
|
gptkbp:UniProtID |
P29274
|
gptkbp:bfsParent |
gptkb:CHEMBL1230992
gptkb:CHEMBL1743027 gptkb:CHEMBL1743088 gptkb:CHEMBL2104662 |
gptkbp:bfsLayer |
8
|